Long-Term Safety and Tolerability of ABT-126 in Adults With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors: An Open-Label Extension Study for Subjects Completing Study M11-793

Trial Profile

Long-Term Safety and Tolerability of ABT-126 in Adults With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors: An Open-Label Extension Study for Subjects Completing Study M11-793

Discontinued
Phase of Trial: Phase II

Latest Information Update: 13 Jul 2016

At a glance

  • Drugs Nelonicline (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions
  • Sponsors Abbott Laboratories; AbbVie
  • Most Recent Events

    • 25 Mar 2014 According to ClinicalTrials.gov record, status changed from active, no longer recruiting to discontinued.
    • 19 Nov 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
    • 19 Jul 2013 Planned number of patients changed from 350 to 420 as reported by United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top